GlycoMimetics
Develop treatments for diseases as sickle cell and cancer.
HQ location
Gaithersburg, United States
Website
Launch date
Employees
Market cap
$1.0b
loading funding rounds…
Sanofi-Genzyme BioVentures(exited)
NEA(exited)
Alliance Technology Ventures(exited)
Anthem Capital Management(exited)
PTV Healthcare Capital(exited)
Novartis Venture Fund(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (89 %) | (94 %) | (87 %) | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (5470 %) | (63204 %) | (391214 %) | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (5468 %) | (62251 %) | (368994 %) | - | - | - | (758 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4094 % | 37855 % | 200717 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by GlycoMimetics
Edit
ACQUISITION by GlycoMimetics Oct 2024